We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals

23.78 USD
+0.24
1.02%
At close Updated Sep 11, 4:00 PM EDT
Pre-market
After hours
23.78
0.00
0%
1 day
1.02%
5 days
1.32%
1 month
16.45%
3 months
15.83%
6 months
26.69%
Year to date
-10.13%
1 year
-17.09%
5 years
28.89%
10 years
29.24%
 

About: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

Employees: 1,976

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 25%
Neutral 41.7%
Negative 33.3%
Neutral
PRNewsWire
12 days ago
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
Positive
Zacks Investment Research
17 days ago
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for August 14th
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
New Strong Sell Stocks for August 14th
Neutral
Seeking Alpha
1 month ago
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
1 month ago
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.85 per share a year ago.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Negative
MarketBeat
1 month ago
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Neutral
PRNewsWire
1 month ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Negative
Zacks Investment Research
1 month ago
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Neutral
PRNewsWire
1 month ago
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30, 2026, after the market closes on Thursday, August 6, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
Price charts implemented using Lightweight Charts™